GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Growth Rank

NewAmsterdam Pharma Co NV (FRA:KH6) Growth Rank : 0 (As of Dec. 11, 2024)


View and export this data going back to 2022. Start your Free Trial

What is NewAmsterdam Pharma Co NV Growth Rank?

NewAmsterdam Pharma Co NV has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

NewAmsterdam Pharma Co NV Growth Rank Related Terms

Thank you for viewing the detailed overview of NewAmsterdam Pharma Co NV's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

NewAmsterdam Pharma Co NV Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NewAmsterdam Pharma Co NV (FRA:KH6) » Definitions » Growth Rank
Comparable Companies
MDXG VERV AKRO ADMA ICPT SLNO INVA OLMA NVAX COGT OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
NAMS:USA KH6:Germany
Address
Gooimeer 2-35, Naarden, NH, NLD, 1411 DC
Website
https://www.newamsterdampharma.com
NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments.

NewAmsterdam Pharma Co NV Headlines

No Headlines